Kallistatin reduces cancer cell viability and induces apoptosis by increasing miR-34a and p53 expression but reducing miR-21 synthesis, Akt phosphorylation, and Bcl-2 expression in breast cancer cells [44]. The gene discussed is TP53; the disease is breast carcinoma.